CTCBIO Inc.

A060590

KR7060590007

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-28 EDT			5-day change	1st Jan Change
8,050 ^KRW	+1.13%		0.00%	-24.77%

04-24	Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	MT
03-21	CTCBIO Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tranche Update on CTCBIO., Inc.'s Equity Buyback Plan announced on August 22, 2013.

August 20, 2014

From October 1, 2013 to August 21, 2014, the company has repurchased 18,000 shares, representing 0.1% for KRW 318.29 million. With this, the company has completed the repurchase of 130,811 shares, representing 0.75% for KRW 2,907.19 million under the buyback announced on August 22, 2013.

Latest news about CTCBIO Inc.

Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	04-24	MT
CTCBIO Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
An unknown buyer agreed to acquire an unknown minority stake in CTCBIO Inc. for KRW 20 billion.	23-08-15	CI
CTCBIO Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
An unknown buyer agreed to acquire 12.57229% stake in CTCBIO Inc. for KRW30 billion.	23-03-30	CI
CTCBIO Inc. announced that it has received KRW 9.999985977 billion in funding from Bridge Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	21-03-31	CI
CTCBIO Inc. announced that it expects to receive KRW 9.999985977 billion in funding from Bridge Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	21-03-21	CI
CTCBIO Inc. announced that it has received KRW 10 billion in funding from Kiwoom Securities Co., Ltd., Samsung Securities Co.,Ltd., Mirae Asset Daewoo Co., Ltd., Shinhan Financial Investment Co., Ltd	20-09-24	CI
CTCBIO Inc. announced that it expects to receive KRW 10 billion in funding from Kiwoom Securities Co., Ltd., Samsung Securities Co.,Ltd., Mirae Asset Daewoo Co., Ltd., Shinhan Financial Investment Co., Ltd	20-09-22	CI
CTCBIO Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Kiwoom Securities Co., Ltd., Samsung Securities Co.,Ltd., KB Securities Co.,Ltd, Mirae Asset Daewoo Co., Ltd., Shinhan Investment Corp.	18-10-03	CI
CTCBIO Inc. announced that it expects to receive KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Kiwoom Securities Co., Ltd., Samsung Securities Co.,Ltd., KB Securities Co.,Ltd, Mirae Asset Daewoo Co., Ltd., Shinhan Investment Corp. other investors	18-10-01	CI
CTCBIO Inc. announced that it has received KRW 20 billion in funding from Korea Investment Partners Co. Ltd.	17-08-24	CI
CTCBIO Inc. announced that it expects to receive KRW 20 billion in funding from Korea Investment Partners Co. Ltd. and other investors	17-08-21	CI
CTCBIO., Inc.'s Equity Buyback announced on August 8, 2014 has expired.	15-08-03	CI
CTCBIO., Inc.(KOSDAQ:A060590) added to Russell Global Index	15-06-29	CI
Ferring Pharmaceuticals Acquires Novel Drug Delivery Technology from CTCBIO Inc	15-02-23	CI
CTCBIO., Inc.'s Equity Buyback Plan Extended till August 4, 2015.	15-02-04	CI
CTCBIO., Inc. cancelled the acquisition of a Factory in Ansan City from SK Chemicals Ltd.	14-12-16	CI
Tranche Update on CTCBIO., Inc.'s Equity Buyback Plan announced on August 8, 2014.	14-11-10	CI
CTCBIO., Inc. acquired drug manufacturing division of SK Chemicals Co.,Ltd.	14-09-29	CI
CTCBIO., Inc.'s Equity Buyback announced on August 22, 2013 has expired with 130,811 shares, representing 0.75% for KRW 2,907.19 million.	14-08-21	CI
Tranche Update on CTCBIO., Inc.'s Equity Buyback Plan announced on August 22, 2013.	14-08-20	CI
CTCBIO., Inc. announces an Equity Buyback for KRW 3,000 million worth of its shares.	14-08-07	CI
CTCBIO., Inc. authorizes a Buyback Plan.	14-08-07	CI
Tranche Update on CTCBIO., Inc.'s Equity Buyback Plan announced on August 22, 2013.	13-11-21	CI

Chart CTCBIO Inc.

Duration

Period

More charts

Company Profile

CTCBIO Inc. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals, veterinary drugs, animal feed supplements and functional foods. It pharmaceuticals include anticancer agents, antibiotics, bone injury treatments, antiulcer agents, blood flow stimulants and others. Its veterinary drugs include vaccines, antibiotics, immune enhancers, enzymes, organic acid, avian influenza-related agents and others. Its animal feed supplements include pigments, kapok seed meal, sesame meal and others. Its functional food business includes the development and manufacture of enzymes, lactobacillus and related products mainly used in dairy products. It also involves in the development of pharmaceutical manufacturing technology and know-how. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
CTCBIO INC.	-24.77%	140M
ELANCO ANIMAL HEALTH INCORPORATED	+16.78%	8.47B
BLUESTAR ADISSEO COMPANY	+24.50%	3.69B
VIRBAC	-2.36%	3.2B
VIMIAN GROUP AB	+11.15%	1.67B
JINYU BIO-TECHNOLOGY CO., LTD.	-11.61%	1.48B
VETOQUINOL SA	-0.78%	1.31B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-24.87%	1.26B
WUHAN KEQIAN BIOLOGY CO.,LTD	-16.73%	1.1B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-5.61%	991M